The American biotechnology company Life Biosciences announced last week that it has administered the first experimental treatment ER-100 to a patient suffering from glaucoma, one of the main causes of blindness. The therapy pursues a goal that until recently seemed taken from science fiction literature: to cause aged cells to behave like young cells again, according to articles published by Business Insider, Nature and Science Alert. The sources cited claim that, if the experiment succeeds, it